Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: Simultaneous determination by a high performance liquid chromatography with electrochemical detection

Pharmacopsychiatry

Volumn 31, Issue 3, 1998, Pages 102-109

  Aravagiri, M ^a   Marder, S R ^a   Wirshing, Donna ^a   Wirshing, W C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; BENZATROPINE; CAFFEINE; CARBAMAZEPINE; CHLORPROMAZINE; CIMETIDINE; CLOMIPRAMINE; CLONAZEPAM; CLOZAPINE; DESIPRAMINE; DRUG METABOLITE; FLUPHENAZINE; IBUPROFEN; IMIPRAMINE; LORAZEPAM; LOXAPINE; PALIPERIDONE; PARACETAMOL; PERPHENAZINE; PSEUDOEPHEDRINE; R 33547; R 78251; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; SELEGILINE; SPIPERONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0031831250     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979308     Document Type: Article

References (28)

1. American Psychiatric Association (APA): Diagnostic and statistical manual of mental disorders, 35the ed. Revised (DSM-III-R). APA, Washington, 1987
2. Aravagiri, M., S. R. Marder, T. Van Putten, K. K. Midha: Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: Application to therapeutic drug monitoring in schizophrenic patients. J. Pharm. Sci. 82 (1993) 447-449
3. Beijsterveldt, L. E. C., R. J. F. Geerts, J. E. Leysen, A. A. H. P. Megens, H. M. J. van den Eynde, W. E. G. Meuldermans, J. J. P. Heykants: Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology 114 (1994) 53-62
4. 2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with RSP (R 64 766). Human Psychopharmacology 5 (1990) 225-231
5. Borison, R. L: Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J. Clin. Pharmacol. 15 Suppl. 1 (1995) 24 S-29 S
6. Borison, R. L., B. Diamond, A. Pathiraja, R. C. Meibach: pharmacokinetics of risperidone in chronic schizophrenic patients. Psychopharmacology Bull. 30 (1994) 193-197
7. Chouinard, G.: Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study J. Clin. Pharmacol. 15, Suppl. 1 (1995) 36 S-44 S
8. Creese, L., D. R. Burt, S. H. Snyder: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192 (1976) 481-483
9. Ellenbroek, B. A.: Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacology and Therapeutics 57 (1993) 1-78
10. 2 receptor binding in risperidone-treated schizophrenic patients. J. Clin. Pharmacol. 15, Suppl. 1 (1995) 19 S-23 S
11. Gerlach, J., L. Peacock: New antipsychotics: the present status. International Clin. Psychopharmacology 10 Suppl. 3 (1995) 39-48
12. 2 receptors. International Clin. Psychopharmacology 10 (1995) 19-30
13. Huang, M. Y., A. van Peer, R. Woestenborghs, R. De Coster, J. Heykants, A. A. I. Jansen, Z. Sylicz, H. W. Visscher, J. H. G. Jonkman: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. And Therapeutics 54 (1993) 257-268
14. Janssen, P. A. J., C. J. F. Niemegeers, F. Awouters, K. H. L. Schellekens, A. A. H. P. Megens, T. F. Meert: Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin- S2 and dopamine-D2 antagonistic properties. J. Pharmacol. Exp. Ther. 244 (1988) 685-693
15. Kane, J., G. Honigfeld, J. Singer, H. Meltzer: The Clozaril collaborative study group: Clozapine for the treatment resistant schizophrenic. Arch. Gen. Psychiatry 45 (1988) 789-796
16. Le Moing, J. P., S. Edouard, J. C. Levron: Determination of risperidone and 9-hydroxy-risperidone in human plasma by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B. 614 (1993) 333-339
17. Leysen, J. E., W. Gommeren, A. Eens, D. de Chaffoy de Coucelles, J. C. Stoof, P. A. J. Janssen: Biochemical profile of risperidone, a new antipsychotic. J. Pharmacol. Exp.Ther. 247 (1988) 661-670
18. Lindström, E., B. Eriksson, A. Hellgren, L. von Knorring, G. Eberhard: Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clinical Therapeutics 17 (1995) 402-412
19. Möller, H.-J.: The Psychopharmacology of schizophrenia: an integrated view on positive symptoms and negative symptoms. International Clin. Psychopharmacology 10 Suppl. 3 (1995) 57-64
20. Mannens, G., M. Y. Huang, W. Meuldermans, J. Hendrickx, R. Woestenborghs, J. Heykants: Absorption, metabolism, and excretion of risperidone in humans. Drug Metab. Disposition 21 (1993) 1134-1141
21. Megens, A. A. H. P., F. H. L. Awouters, A. Schotte, T. F. Meert, C. Dugovic, C. J. E. Niemegeers, J. E. Leysen: Survey of pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 114 (1994) 9-23
22. Meltzer, H. Y., S. Matsubara, J. C. Lee: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251 (1989) 238-246
23. Meuldermans, W., J. Hendrickx, G. Mannens, K. Lavrjsen, C. Janssen, J. Bracke, L. Le Jeune, W. Lauwers, J. Heykants: The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab. Disposition 22 (1994) 129-138
24. 2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology 119 (1995) 345-348
25. Schotte, A., P. F. M. Janssen, W. Gommeren, W. H. M. L. Luyten, P. van Gompel, A. S. Lesage, De Loore, J. E. Leysen: Risperidone compared with new and reference antipsychotic drugs: in vitro und in vivo receptor binding. Psychopharmacology 124 (1996) 57-73
26. Seeman, P., T. Lee: Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188 (1975) 1217-1219
27. Seeman, P.: Therapeutic receptor-blocking concentrations of neuroleptics. International Clin. Psychopharmacology 10 Suppl. 3 (1995) 5-13
28. Woestenborghs, R., W. Lorreyne, F. van Rompaey, J. Heykants: Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography. J. Chromatogr. B. 583 (1992) 223-230